Brendan Foody, a prominent tech journalist, has been investigating allegations of a valuation battle between Seacoia and its client, a major biotech firm. The investigation has revealed a disturbing pattern where both firms offer the same valuation for the same technology. This has sparked concerns about fairness in the industry.
Foody's research suggests that Seacoia is one of many top firms that engage in this practice, known as "same equity" or "double pricing." This tactic allows the firm to secure more business by presenting itself with a lower valuation, potentially allowing it to command higher prices for future investments. The practice has raised eyebrows among industry insiders, who argue that it can lead to unfair treatment of smaller firms.
Seacoia's own statements have been largely silent on the matter, but Foody obtained documents and communications from various stakeholders that reveal the firm's involvement in the same equity scandal. While Seacoia denies any wrongdoing, its actions appear to be driven by a desire for more lucrative business opportunities rather than a genuine commitment to fairness. The implications of this practice are far-reaching, with potential consequences for investors and smaller firms alike.
